Data Safety Monitoring Boards

What is a DSMB?
A Data and Safety Monitoring Board (DSMB) is an independent group of experts that advises the sponsor and the study investigators. The members of the DSMB serve in an individual capacity and provide their expertise and recommendations. Other names for committees that monitor accumulating data are Data Monitoring Committee (DMC) and Data Safety Monitoring Committee (DSMC). In a 2006 guidance document, the FDA defined a DMC as “a group of individuals with pertinent expertise that reviews on a regular basis accumulating data from one or more ongoing clinical trials. The DMC advises the sponsor regarding the continuing safety of trial subjects and those yet to be recruited to the trial, as well as the continuing validity and scientific merit of the trial”. [http://www.fda.gov/OHRMS/DOCKETS/98fr/01d-0489-gdl0003.pdf](http://www.fda.gov/OHRMS/DOCKETS/98fr/01d-0489-gdl0003.pdf)

What is the Purpose of a DSMB?
The DSMB evaluates research data on an ongoing basis to assure participant safety and study integrity. The DSMB periodically reviews study data and unanticipated problems and makes recommendations based on their reviews along with assessing the performance of overall study operations and any other relevant issues, as necessary.

Independence of the DSMB
It is essential that the judgment of members of the DSMB not be influenced by factors other than those necessary to maintain subject safety and to preserve the integrity of the study. Persons who have an apparent financial, intellectual, or other interests with a drug, device, or procedure should not be a DSMB participant for the evaluation of that product. Independence is essential to ensure that DSMB members are objective and capable of an unbiased assessment of the study’s safety and efficacy data. The following will ensure the independence of the DSMB:

- Members of the DSMB will not participate as investigators in this study and are not supervised by study investigators.
- Members of the DSMB must not have a direct interest in knowing or influencing trial outcome or have a financial or intellectual interest in the outcome of this study.
• DSMB members must disclose all pharmaceutical companies, biotechnology companies, and CROs in which they hold financial interest. Members must disclose all consultancies (direct or indirect) with pharmaceutical companies, biotechnology companies, and CROs.
  o Members of the DSMB will be responsible for notifying the DSMB Chair and the Sponsor/Sponsor-Investigator of any changes of interest in pharmaceutical companies, biotechnology companies, or CROs, including consultancies. Members will be polled at the beginning of each DSMB meeting to disclose whether status has changed and this will be reflected in meeting minutes.

**Do the regulations require DSMBs?**

The regulations provide minimal insight on DSMBs. The Code of Federal Regulations indirectly address data safety monitoring in 45 CFR 46.111 (a)(6) which states “When appropriate, the research plan makes adequate provision for monitoring the data collected to ensure the safety of subjects.”

The 2006 FDA guidance document discusses the roles, responsibilities, and operating procedures of DMCs. This document is helpful in determining whether a DMC is needed and how it should function. Some government agencies that sponsor clinical research have required the use of DMCs in certain clinical trials. Current FDA regulations, however, impose no requirements for the use of DMCs in trials except under 21 CFR 50.24(a)(7)(iv) for research studies in emergency settings in which the informed consent requirement is excepted. Though it is not required, the FDA generally expects the use of a DMC for randomized trials with mortality or major morbidity as primary endpoints.

**Do I need a DSMB?**

While it is important to remember that all studies require a DSMP and careful monitoring, it is also important to know that not all studies require DSMBs. Some studies have too few subjects to support statistical analysis by a DSMB, but must have a clinical safety monitoring mechanism. Some trials do not require a DSMB for other reasons; for example, early phase non-randomized trials with limited safety concerns. Additionally, studies with rapid recruitment and short-term endpoints may not be long enough for a DSMB to be of any use.

The following questions are designed to help make a determination as to whether or not a DSMB may be needed.

- Is there a large study population, or are there multiple study sites?
- Is the trial intended to provide definitive information about effectiveness and/or safety of a medical intervention?
- Do prior data suggest that the intervention being studied has the potential to induce unacceptable toxicity?
- Does the trial evaluate mortality or another major endpoint, such that inferiority of one treatment arm has safety and effectiveness implications?
- Would it be ethically important for the trial to stop early if the primary question addressed has been definitively answered, even if secondary questions or complete safety information were not yet fully addressed?
A DSMB usually should be implemented if two or more answers to the above questions are yes.

**Who should be on the DSMB?**

The PI or trial sponsor generally appoints the DSMB and should have multidisciplinary representation, including physicians from relevant medical specialties and biostatisticians. When appointing individuals to a DSMB, the following should be considered: relevant expertise, experience in clinical trials, experience as a member of other DSMBs, and a lack of apparent significant Conflicts of Interest, whether they are financial, intellectual, professional, or regulatory in nature. The appropriate size of a DSMB will depend upon the particular study and types of expertise needed. A DSMB may consist of as few as three members, but this number should be large enough to include a representation of all needed skills and experience.

Who is typically included in a DSMB?
- Clinicians with expertise in relevant clinical specialties
- At least one biostatistician knowledgeable about analysis of trial data

Who might also be included in a DSMB?
- Medical ethicist
- Other types of scientists (i.e., clinical pharmacologist, toxicologist, epidemiologist, laboratory scientist, etc.)

Best practice is to include an appropriate representation of gender and ethnic groups.

**What are the responsibilities of the DSMB?**

The primary responsibility of the DSMB is to safeguard the interest of study participants. Therefore, the DSMB must approve the safety measures in the protocol to preserve the study credibility and facilitate the availability of timely and reliable findings to the broader clinical community.

In addition, the DSMB should:
- Provide written documentation confirming review of the protocol and agreement with the study design and the data safety monitoring plan (DSMP).
- Review the progress of the study carefully and diligently. The DMC or DSMB should assure that all significant Adverse Events are reported to the IRB according to policies and procedures.
- Be available to the Investigator for consultation concerning any adverse study events.
- Consider the impact of newly published findings bearing on the safety profile of the study.
- Provide a written report to the IRB which summarizes oversight activities and recommendations, and any concerns regarding subject safety.

**DSMB Charter Template:**

Version 1/11/2022
What is the role of the IRB with regard to DSMBs and DSMPs?

Reviewing the DSMP and all DSMB reports is a part of the IRB initial approval and subsequent reapproval. The IRB does not typically have access to the interim data, but the IRB may take action based on recommendations from the DSMB. The IRB must still review internal AEs and UPs involving risks to subjects or other and any information to ensure that the review is meaningful.

IRB review includes:

Initial Assessment of the Overall Monitoring Plan:
The IRB should assess the overall Monitoring Plan for adequacy in detecting and addressing safety issues AND ensuring protocol compliance and data quality.

Monitoring Plan Components:

- Data Safety Monitoring Plan – How is safety information collected from sites and from other sources (e.g., other studies, other countries where drug is approved, etc.); evaluated; and results disseminated to investigators?
- Data Safety Monitoring Board (DSMB) – Who will review safety data, consider stopping rules, etc.?
- Site Monitoring Plan – How is information being collected about protocol compliance at each site and the quality of the data being collected?
- Review of Monitoring Plan Results: Ensure that Site Monitoring results are reviewed by investigator and events that impact subject safety or data integrity are reported per IRB requirements.
- At continuing review, IRB should review and assess DSMB reports and overall DSMP.

Where can I find more information about DSMBs and DSMPs?

- Guidance for Clinical Trial Sponsors On the Establishment and Operation of Clinical Trial Data Monitoring Committees March (2006)
- The Emory IRB Policies and Procedures: Section 50 Data and Safety Monitoring Plans
- NIH/NIAID Policies, Guidelines and Sample Documents for Clinical Trials
- NIH Policies and IC Guidance for Data and Safety Monitoring of Clinical Trials
- NIAID Decision Tree for Data and Safety Monitoring Plan